Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026
Company Deals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Fineline Cube Feb 26, 2026
Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

Fineline Cube Feb 26, 2026
Company Drug

3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Fineline Cube Feb 26, 2026
Company Medical Device

Venus Medtech’s VenusP-Valve Receives Marketing Approval in Venezuela, Expanding Global Reach

Fineline Cube Jul 19, 2024

Venus Medtech (Hangzhou) Inc., (HKG: 2500), a leading medical device company, has announced that it...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers

Fineline Cube Jul 19, 2024

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has...

Company Medical Device

Shanghai Sanyou Medical’s Cervical Thoracic Internal Fixation System Earns NMPA Approval

Fineline Cube Jul 19, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a leading medical device company based in China,...

Company Deals

Suzhou New District Hi-tech Industrial Co., Ltd and Subsidiaries to Establish Biopharmaceutical FOF with SND Group

Fineline Cube Jul 19, 2024

Suzhou New District Hi-tech Industrial Co., Ltd (SHA: 600736), a prominent company in China’s high-tech...

Company Deals

NeuShen Therapeutics and Livzon Pharma Strike Deal for Greater China Rights to NS-041

Fineline Cube Jul 19, 2024

NeuShen Therapeutics, a Sino-US biopharmaceutical company, has entered into a licensing agreement with Livzon Pharmaceutical...

Policy / Regulatory

NHSA Mandates Standardized Online Procurement for Injectable Drugs to Ensure Pricing Transparency

Fineline Cube Jul 18, 2024

The National Healthcare Security Administration (NHSA) has issued a directive to standardize the procurement process...

Company Drug

Consun Pharmaceutical Gets NMPA Go-Ahead for CKD Drug Clinical Trial

Fineline Cube Jul 18, 2024

Consun Pharmaceutical Group Ltd (HKG: 1681), a leading Chinese pharmaceutical company, has announced that it...

Company Drug

Shanghai Ruijin Hospital’s Hainan Subsidiary Adopts ANI Pharmaceuticals’ Veregen for HPV Treatment

Fineline Cube Jul 18, 2024

ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented...

Company Deals

Roche’s Genentech Terminates Relay Therapeutics Collaboration for SHP2 Inhibitor

Fineline Cube Jul 18, 2024

In a recent development, Roche Inc.’s subsidiary Genentech has given notice of termination for a...

Company

Johnson & Johnson Reports Robust Q2 2024 Earnings, Bolstered by Pharma and Medtech Growth

Fineline Cube Jul 18, 2024

Johnson & Johnson (NYSE: JNJ) has reported its financial results for the second quarter of...

Company Deals

Shanghai Escugen and Sidewinder Therapeutics Form Strategic Alliance for ADC Development

Fineline Cube Jul 18, 2024

Shanghai Escugen, a leading biopharmaceutical company specializing in antibody drug conjugates (ADCs), has announced a...

Company Drug

Junshi Biosciences’ Loqtorzi Inches Closer to Expanded Indication with NMPA Filing Acceptance

Fineline Cube Jul 18, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has taken a significant step forward...

Company Deals

SYNYI.AI Secures New Funding to Accelerate Digital Transformation in Healthcare

Fineline Cube Jul 18, 2024

Shanghai’s SYNYI.AI, a pioneering medical data mining and governance platform, has reportedly closed a new...

Company Deals

Boston Scientific Secures Silk Road Medical in a $1.16B Deal to Fortify Stroke Prevention Portfolio

Fineline Cube Jul 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical devices, has announced a definitive...

Company Deals

China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions

Fineline Cube Jul 18, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of...

Company Drug

Everest Medicines’ Nefecon Receives NMPA Review, Signaling Potential Treatment Milestone for IgAN Patients

Fineline Cube Jul 18, 2024

Everest Medicines (HKG: 1952), a biopharmaceutical company dedicated to addressing critical medical needs in Asian...

Company

Sanofi to Bolster Hyderabad Facility with $437M Investment, Eyeing Tech Upgrades

Fineline Cube Jul 18, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), a leading French multinational pharmaceutical company, has announced plans to...

Company Deals

CR Boya Bio-Pharmaceutical’s Strategic Foray: Acquiring Green Cross HK for $250M to Expand Biopharma Dominance

Fineline Cube Jul 18, 2024

In a significant development for the biopharmaceutical industry, China Resources Medical Holdings Company Limited and...

Company Drug

Grand Pharmaceutical Gets Nod for Phase II Sepsis Study of STC3141 in China

Fineline Cube Jul 18, 2024

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced that it has...

Company Deals

Guotai Junan and Haitong Securities to Launch $10 Billion in Industry Funds in Shanghai

Fineline Cube Jul 17, 2024

China’s prominent financial institutions, Guotai Junan Securities and Haitong Securities, have revealed plans to establish...

Posts pagination

1 … 289 290 291 … 627

Recent updates

  • NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge
  • Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations
  • NMPA CDE Opens Public Consultation for 104th Reference Listed Drugs Catalog – 63 Specifications Under Review
  • Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader
  • Novartis to Build $23B RLT Manufacturing Site in Texas – Expands Radioligand Therapy Production Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Company Drug

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

Policy / Regulatory

NMPA CDE Opens Public Consultation for 104th Reference Listed Drugs Catalog – 63 Specifications Under Review

Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.